Skip to main content
Clinical Trials/NCT05556967
NCT05556967
Completed
Phase 3

Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM in Normal Humans

University of Mississippi Medical Center1 site in 1 country20 target enrollmentAugust 9, 2023
InterventionsImmulina

Overview

Phase
Phase 3
Intervention
Immulina
Conditions
Adherence, Patient
Sponsor
University of Mississippi Medical Center
Enrollment
20
Locations
1
Primary Endpoint
palmitoleic acid, ug/mL
Status
Completed
Last Updated
11 months ago

Overview

Brief Summary

This is a pilot study for identifying plasma and/or urine-derived adherence/surrogate biomarker candidates for verifying Immulina™ ingestion by human volunteers (collected before and after consumption of Immulina™, a natural dietary supplement).

Detailed Description

This pilot study is interventional, and all participants will receive one 800 mg dose of Immulina™ (four 200 mg capsules), a natural supplement, after a baseline blood and urine collection, then follow with 1 hour, 3 hour and 6 hour post-Immulina™ blood and urine collections. Samples will be sent to UM National Center for Natural Products Research (NCNPR) to analyze and compare timed blood and urine samples using gas chromatography and liquid chromatography to detect volatile and non-volatile compounds, gamma-linolenic acid (GLA), sulfoquinovose (SQ), 5'-methylsulfinyladenosine (MSA), palmitic acid, linoleic acid, palmitoleic acid and oleic acid to screen the chemical fingerprints of the human samples. The mean of the 7 biomarkers for the 4 time points will be measured and compared.

Registry
clinicaltrials.gov
Start Date
August 9, 2023
End Date
October 19, 2023
Last Updated
11 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males and females, 18-50 years old
  • If female of childbearing potential, using acceptable means of birth control or postmenopausal for at least two years

Exclusion Criteria

  • pregnant or lactating females
  • significant acute disease
  • recurrent medications for chronic disease

Arms & Interventions

Immulina Dietary Supplementation

Immulina Dietary Supplementation (200 mg per capsule) 4-200 mg capsules given by mouth once on the only study visit day.

Intervention: Immulina

Outcomes

Primary Outcomes

palmitoleic acid, ug/mL

Time Frame: Over 7 hour period

Differences in palmitoleic acid between baseline, 1 hour post-Immulina, 3 hour post-Immulina and 6 hour post-Immulina

steric acid, ug/mL

Time Frame: Over 7 hour period

Differences in steric acid between baseline, 1 hour post-Immulina, 3 hour post-Immulina and 6 hour post-Immulina

gamma-linolenic acid (GLA), ug/mL

Time Frame: Over 7 hour period

Differences in GLA between baseline, 1 hour post-Immulina, 3 hour post-Immulina and 6 hour post-Immulina

5'-methylsulfinyladenosine (MSA), ug/mL

Time Frame: Over 7 hour period

Differences in MSA between baseline, 1 hour post-Immulina, 3 hour post-Immulina and 6 hour post-Immulina

linoleic acid, ug/mL

Time Frame: Over 7 hour period

Differences in linoleic acid between baseline, 1 hour post-Immulina, 3 hour post-Immulina and 6 hour post-Immulina

Sulfoquinovose (SQ), ug/mL

Time Frame: Over 7 hour period

Differences in SQ between baseline, 1 hour post-Immulina, 3 hour post-Immulina and 6 hour post-Immulina

palmitic acid, ug/mL

Time Frame: Over 7 hour period

Differences in palmitic acid between baseline, 1 hour post-Immulina, 3 hour post-Immulina and 6 hour post-Immulina

oleic acid, ug/mL

Time Frame: Over 7 hour period

Differences in oleic acid between baseline, 1 hour post-Immulina, 3 hour post-Immulina and 6 hour post-Immulina

Study Sites (1)

Loading locations...

Similar Trials